aspartic acid has been researched along with Hypoxia in 88 studies
Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter.
aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent
L-aspartic acid : The L-enantiomer of aspartic acid.
Hypoxia: Sub-optimal OXYGEN levels in the ambient air of living organisms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The releases of endogenous glutamate, aspartate, GABA and taurine from hippocampal slices from 7-day-, 3-, 12-, and 18-month-old mice were investigated under cell-damaging conditions using a superfusion system." | 7.70 | Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions. ( Oja, SS; Saransaari, P, 1998) |
| "Medulloblastoma is a cancerous brain tumor that affects mostly children." | 5.91 | The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment. ( Ben-Sahra, I; Bost, F; Contenti, J; Guo, Y; Irondelle, M; Lago, C; Leva, G; Mazure, NM; Mazzu, A; Rouleau, M; Tiberi, L, 2023) |
| "In response to Mycobacterium tuberculosis infection, macrophages mount proinflammatory and antimicrobial responses similar to those observed in M1 macrophages activated by lipopolysaccharide (LPS) and interferon gamma (IFN-γ)." | 5.72 | Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. ( Drlica, K; Jiang, Q; Kurland, IJ; Qiu, Y; Shi, L; Subbian, S; Tyagi, S, 2022) |
| "1." | 5.29 | Lidocaine reduces the hypoxia-induced release of an excitatory amino acid analog from rat striatal slices in superfusion. ( Bustos, G; Díaz, L; Gómez, A, 1995) |
| "The effects of hydrogen sulfide (H(2)S) and acute hypoxia are similar in isolated pulmonary arteries from various species." | 3.78 | Precursors and inhibitors of hydrogen sulfide synthesis affect acute hypoxic pulmonary vasoconstriction in the intact lung. ( Ahlf, SB; Dantuma, MW; Madden, JA; Olson, KR; Roerig, DL, 2012) |
| "The ventilatory response to hypoxia is influenced by the balance between inhibitory (GABA, glycine, and taurine) and excitatory (glutamate and aspartate) brainstem amino acid (AA) neurotransmitters." | 3.74 | Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets. ( Bancalari, E; Devia, CJ; Hehre, DA; Suguihara, C, 2008) |
| "Acute hypoxia increases cerebral lactate and alanine in NG chick embryos; these increases are reduced by pre-exposure to substrate deprivation and chronic hypoxia." | 3.73 | Growth restriction and the cerebral metabolic response to acute hypoxia of chick embryos in-ovo: a proton magnetic resonance spectroscopy study. ( Cady, EB; Dixon, JC; Peebles, DM; Priest, AN; Thornton, JS, 2005) |
| "Lactate accumulation, amino acid aspartate and glutamate levels, and hypoxanthine, xanthine and malondialdehyde (MDA) concentrations were compared in neonate rat brain after transient global hypoxia induced alone or in association with unilateral ligation of a carotid artery." | 3.70 | Changes in excitatory amino acid levels and tissue energy metabolites of neonate rat brain after hypoxia and hypoxia-ischemia. ( Barrier, L; Chalon, S; Guerraoui, A; Guilloteau, D; Huguet, F; Tallineau, C, 1998) |
| "Ventilation, oxygen consumption, the ventilatory equivalent for oxygen, and ventilatory responses to hypoxia and to hypercapnia were evaluated in conscious male rats who received each of four treatments: (1) microinjection of artificial cerebrospinal fluid (aCSF) into the arcuate nucleus and subcutaneously saline (CS); (2) aspartic acid into the arcuate nucleus and saline subcutaneously (AS); (3) aCSF into the arcuate nucleus and naloxone subcutaneously (CN); and (4) aspartic acid into the arcuate nucleus and naloxone subcutaneously (AN)." | 3.70 | Aspartic acid in the arcuate nucleus attenuates the depressive effects of naloxone on ventilation. ( Schlenker, EH, 1998) |
| "The releases of endogenous glutamate, aspartate, GABA and taurine from hippocampal slices from 7-day-, 3-, 12-, and 18-month-old mice were investigated under cell-damaging conditions using a superfusion system." | 3.70 | Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions. ( Oja, SS; Saransaari, P, 1998) |
| " The purpose of this study was to test the hypothesis that a short period of hypoxia would affect release of excitatory and inhibitory amino acids during subsequent bicuculline-induced seizure." | 3.68 | Hypoxia increases extracellular concentrations of excitatory and inhibitory neurotransmitters in subsequently induced seizure: in vivo microdialysis study in the rabbit. ( Aquila, WJ; During, MJ; Ley, E; Tendler, D; Young, RS, 1992) |
| " By using this system of graded hypoxia a comparison was made between rates of gluconeogenesis from lactate, serine and aspartate in the whole animal and the concentrations of several liver metabolites." | 3.65 | Regulation of gluconeogenesis during exposure of young rats to hypoxic conditions. ( Ballard, FJ, 1971) |
| "In examining the content of free ammonia, glutamine and some free amino acid s in the brain tissue of mice under normal conditions, in hypoxia and under the effect of succinic acidsemialdehyde, in hypoxia there was revealed a marked increase in comparison with the normal conditions) of the content of free ammonia, and alpha-alanine, a reduction of glutamine; there was also a slight elevation in the content of gamma aminobutyric acid and no changes in glutamic and asparagic acid content." | 3.65 | [Effect of succinic semialdehyde on nitrogen metabolism of animal brain tissue during hypoxia]. ( Ostrovskaia, RU; Safronova, MI; Tsybina, NM; Zubovskaia, AM, 1976) |
| "Creatine is a naturally occurring compound involved in the buffering, transport, and regulation of cellular energy, with the potential to replenish cellular adenosine triphosphate without oxygen." | 2.80 | Creatine supplementation enhances corticomotor excitability and cognitive performance during oxygen deprivation. ( Byblow, WD; Gant, N; Turner, CE, 2015) |
| "Medulloblastoma is a cancerous brain tumor that affects mostly children." | 1.91 | The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment. ( Ben-Sahra, I; Bost, F; Contenti, J; Guo, Y; Irondelle, M; Lago, C; Leva, G; Mazure, NM; Mazzu, A; Rouleau, M; Tiberi, L, 2023) |
| "In response to Mycobacterium tuberculosis infection, macrophages mount proinflammatory and antimicrobial responses similar to those observed in M1 macrophages activated by lipopolysaccharide (LPS) and interferon gamma (IFN-γ)." | 1.72 | Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection. ( Drlica, K; Jiang, Q; Kurland, IJ; Qiu, Y; Shi, L; Subbian, S; Tyagi, S, 2022) |
| "Guanosine (GUO) has been shown to act as a neuroprotective agent against glutamatergic excitotoxicity by increasing glutamate uptake and decreasing its release." | 1.43 | Neuroprotection Promoted by Guanosine Depends on Glutamine Synthetase and Glutamate Transporters Activity in Hippocampal Slices Subjected to Oxygen/Glucose Deprivation. ( Coelho, V; Dal-Cim, T; Lanznaster, D; Martins, WC; Poluceno, GG; Tasca, CI; Thomaz, DT; Vandresen-Filho, S, 2016) |
| "We demonstrate the absence of reactive gliosis in the immature white matter following chronic hypoxia, as determined by astrocyte proliferation index and glial fibrillary acidic protein levels." | 1.37 | Chronic perinatal hypoxia reduces glutamate-aspartate transporter function in astrocytes through the Janus kinase/signal transducer and activator of transcription pathway. ( Gallo, V; Huntsman, M; Li, P; Mangin, JM; Raymond, M, 2011) |
| "After a stabilization period, prolonged hypoxemia (FiO(2): 0." | 1.33 | Excitatory amino acid release and electrocortical brain activity after hypoxemia in near-term lambs. ( Hopman, J; Ruitenbeek, W; van de Bor, M; van Os, S, 2006) |
| "Exposure to anoxia caused an increase in the levels of succinate (6 and 18 h) and acetate and propionate (18 h) with respect to control specimens." | 1.31 | Metabolic responses of the limpet Patella caerulea (L.) to anoxia and dehydration. ( Bruschini, C; Chelazzi, G; Moneti, G; Pazzagli, L; Pieraccini, G; Santini, G, 2001) |
| "As the effects of ischemia or anoxia on glutamate and aspartate release from the heart appear to be comparable to those observed in the brain, it is proposed that the heart preparation may be a suitable model in which to study the ischemia-evoked release of these amino acids in the absence of complications arising from their depolarizing and excitotoxic actions on central neurons." | 1.29 | Release of the excitotoxic amino acids, glutamate and aspartate, from the isolated ischemic/anoxic rat heart. ( O'Regan, MH; Phillis, JW; Song, D, 1996) |
| "1." | 1.29 | Lidocaine reduces the hypoxia-induced release of an excitatory amino acid analog from rat striatal slices in superfusion. ( Bustos, G; Díaz, L; Gómez, A, 1995) |
| "The effects of anoxia on the brain concentrations of gamma-aminobutyric acid (GABA), glutamate, aspartate, glutamine, alanine, and taurine were measured in the shore crab (Carcinus maenas) and compared with data previously obtained from anoxia-tolerant vertebrates." | 1.29 | Changes in the brain levels of GABA and related amino acids in anoxic shore crab (Carcinus maenas). ( Nilsson, GE; Winberg, S, 1993) |
| "Ten minutes of anoxia produced significant elevation of glutamate (from 0." | 1.29 | Effect of anoxia on excitatory amino acids in brain slices of rats and turtles: in vitro microdialysis. ( Aquila, WJ; Donnelly, DF; During, MJ; Haddad, GG; Perry, VL; Young, RS, 1993) |
| "Previous studies show that (1) hypoxemia depletes immature myocardium of amino acid substrates and their replenishment improves ischemic tolerance, (2) reoxygenation on cardiopulmonary bypass causes oxygen-mediated damage without added ischemia, and (3) this damage may be related to the nitric oxide-L-arginine pathway that is affected by amino acid metabolism." | 1.29 | Studies of hypoxemic/reoxygenation injury: without aortic clamping. VIII. Counteraction of oxidant damage by exogenous glutamate and aspartate. ( Buckberg, GD; Ihnken, K; Matheis, G; Morita, K; Sherman, MP; Young, HH, 1995) |
| "Protein synthesis was impaired after anoxia; the extent of inhibition was dependent on the duration of anoxia and on the time allowed for postanoxic recovery." | 1.28 | Activation of excitatory amino acid receptors cannot alone account for anoxia-induced impairment of protein synthesis in rat hippocampal slices. ( Carter, AJ; Müller, RE, 1991) |
| "Chemically induced hypoglycemia and anoxia were evaluated in embryonic day 13 chicken retina to determine if excitotoxicity was a consequence of these conditions and if this was preceded by the net release of glutamate or aspartate." | 1.28 | Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina. ( Nicklas, WJ; Zeevalk, GD, 1990) |
| "We have previously reported that chronic administration of valproate in developing mice decreased brain aspartic and glutamic acid levels and increased the brain taurine content." | 1.28 | Valproate doubles the anoxic survival time of normal developing mice: possible relevance to valproate-induced decreases in cerebral levels of glutamate and aspartate, and increases in taurine. ( Hauhart, RE; Thurston, JH, 1989) |
| "1." | 1.28 | Anoxia on slow inward currents of immature hippocampal neurons. ( Ben-Ari, Y; Cherubini, E; Krnjević, K, 1989) |
| "After 10 min of anoxia the dentate granule cells recovered to 16 +/- 7% (mean +/- SE) of their preanoxic level when untreated and to 54 +/- 15% when treated with aminophosphonovaleric acid (APV)." | 1.28 | The N-methyl-D-aspartate antagonists aminophosphonovaleric acid and MK-801 reduce anoxic damage to dentate granule and CA1 pyramidal cells in the rat hippocampal slice. ( Chambers, G; Cottrell, JE; Kass, IS, 1989) |
| "During anoxia the contribution of glycolysis to the required energy is enhanced from 44% (after 2 h) to 86% (after 15 h)." | 1.27 | The pyruvate branchpoint in the anaerobic energy metabolism of the jumping cockle Cardium tuberculatum L.: D-lactate formation during environmental anaerobiosis versus octopine formation during exercise. ( Gäde, G; Meinardus-Hager, G, 1986) |
| "Hypoglycemia or anoxia alone affected the release only marginally." | 1.27 | Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro. ( Benveniste, H; Diemer, NH; Drejer, J; Schousboe, A, 1985) |
| "Aspartic acid-treated females breathed with a smaller tidal volume (VT), higher frequency (f), and similar minute ventilation (VE) compared with control females." | 1.27 | Aspartic acid administered neonatally affects ventilation of male and female rats differently. ( Goldman, M; Schlenker, EH, 1986) |
| "The effect of anoxia and ischemia on the release of amino acid transmitters from cerebellar slices induced by veratridine or high [K+] was studied." | 1.27 | Effects of anoxia on the stimulated release of amino acid neurotransmitters in the cerebellum in vitro. ( Balázs, R; Bosley, TM; Gordon, RD; Woodhams, PL, 1983) |
| "Effects of glucose concentration and anoxia upon the metabolite concentrations and rates of glycolysis and respiration have been investigated in the perfused liver of the fetal guinea pig." | 1.26 | Some effects of glucose concentration and anoxia on glycolysis and metabolite concentrations in the perfused liver of fetal guinea pig. ( Faulkner, A; Jones, CT, 1978) |
| "The influence of hypoxemia on the brain content of several organic acids and NH+4, AND ITS RELATIONship to the accompanying hypocapnia was studied in unanesthetized rats subjected to hypoxemia for periods ranging between 2 hours and 7 days." | 1.26 | Brain amino acids in conscious rats in chronic normocapnic and hypocapnic hypoxemia. ( Leusen, I; Van Leuven, F; Weyne, J, 1977) |
| "3." | 1.25 | Concentrations of free glucogenic amino acids in livers of rats subjected to various metabolic stresses. ( Lopes-Vieira, O; Walker, B; Williamson, DH, 1967) |
| "Tetrodotoxin has no accelerative effect on cerebral aerobic glycolysis." | 1.25 | Effects of tetrodotoxin and anaesthetics on brain metabolism and transport during anoxia. ( Quastel, JH; Shankar, R, 1972) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 35 (39.77) | 18.7374 |
| 1990's | 28 (31.82) | 18.2507 |
| 2000's | 16 (18.18) | 29.6817 |
| 2010's | 4 (4.55) | 24.3611 |
| 2020's | 5 (5.68) | 2.80 |
| Authors | Studies |
|---|---|
| Garcia-Bermudez, J | 1 |
| Badgley, MA | 1 |
| Prasad, S | 1 |
| Baudrier, L | 1 |
| Liu, Y | 1 |
| La, K | 1 |
| Soula, M | 1 |
| Williams, RT | 1 |
| Yamaguchi, N | 1 |
| Hwang, RF | 1 |
| Taylor, LJ | 1 |
| de Stanchina, E | 1 |
| Rostandy, B | 1 |
| Alwaseem, H | 1 |
| Molina, H | 1 |
| Bar-Sagi, D | 1 |
| Birsoy, K | 1 |
| Jiang, Q | 1 |
| Qiu, Y | 1 |
| Kurland, IJ | 1 |
| Drlica, K | 1 |
| Subbian, S | 1 |
| Tyagi, S | 1 |
| Shi, L | 1 |
| Wang, Z | 1 |
| Mu, X | 1 |
| Yang, Q | 1 |
| Luo, J | 1 |
| Zhao, Y | 1 |
| Wan, F | 1 |
| Jin, L | 1 |
| Qin, Y | 1 |
| Zeng, Y | 1 |
| Contenti, J | 1 |
| Guo, Y | 1 |
| Mazzu, A | 1 |
| Irondelle, M | 1 |
| Rouleau, M | 1 |
| Lago, C | 1 |
| Leva, G | 1 |
| Tiberi, L | 1 |
| Ben-Sahra, I | 1 |
| Bost, F | 1 |
| Mazure, NM | 1 |
| Turner, CE | 1 |
| Byblow, WD | 1 |
| Gant, N | 1 |
| Dal-Cim, T | 1 |
| Martins, WC | 1 |
| Thomaz, DT | 1 |
| Coelho, V | 1 |
| Poluceno, GG | 1 |
| Lanznaster, D | 1 |
| Vandresen-Filho, S | 1 |
| Tasca, CI | 1 |
| Madden, JA | 1 |
| Ahlf, SB | 1 |
| Dantuma, MW | 1 |
| Olson, KR | 1 |
| Roerig, DL | 1 |
| Raymond, M | 1 |
| Li, P | 1 |
| Mangin, JM | 1 |
| Huntsman, M | 1 |
| Gallo, V | 1 |
| Park, HD | 1 |
| Guinn, KM | 1 |
| Harrell, MI | 1 |
| Liao, R | 1 |
| Voskuil, MI | 1 |
| Tompa, M | 1 |
| Schoolnik, GK | 1 |
| Sherman, DR | 1 |
| LAMARCHE, M | 1 |
| ROYER, R | 1 |
| BAS, M | 1 |
| NAKAMURA, H | 1 |
| GOLDENBERG, AM | 1 |
| Parrot, S | 1 |
| Cottet-Emard, JM | 1 |
| Sauvinet, V | 1 |
| Pequignot, JM | 1 |
| Denoroy, L | 1 |
| Ralphe, JC | 1 |
| Segar, JL | 1 |
| Schutte, BC | 1 |
| Scholz, TD | 1 |
| Büyükuysal, RL | 1 |
| HICKS, JT | 1 |
| Tavazzi, B | 1 |
| Signoretti, S | 1 |
| Lazzarino, G | 1 |
| Amorini, AM | 1 |
| Delfini, R | 1 |
| Cimatti, M | 1 |
| Marmarou, A | 1 |
| Vagnozzi, R | 1 |
| Raman, L | 1 |
| Tkac, I | 1 |
| Ennis, K | 1 |
| Georgieff, MK | 1 |
| Gruetter, R | 1 |
| Rao, R | 1 |
| Dixon, JC | 1 |
| Cady, EB | 1 |
| Priest, AN | 1 |
| Thornton, JS | 1 |
| Peebles, DM | 1 |
| Xu, L | 1 |
| Dayal, M | 1 |
| Ouyang, YB | 1 |
| Sun, Y | 1 |
| Yang, CF | 1 |
| Frydman, J | 1 |
| Giffard, RG | 1 |
| Bonde, C | 1 |
| Noraberg, J | 1 |
| Noer, H | 1 |
| Zimmer, J | 1 |
| van Os, S | 1 |
| Ruitenbeek, W | 1 |
| Hopman, J | 1 |
| van de Bor, M | 1 |
| Molchanova, SM | 1 |
| Oja, SS | 3 |
| Saransaari, P | 3 |
| Lipski, J | 1 |
| Wan, CK | 1 |
| Bai, JZ | 1 |
| Pi, R | 1 |
| Li, D | 1 |
| Donnelly, D | 1 |
| Hehre, DA | 1 |
| Devia, CJ | 1 |
| Bancalari, E | 2 |
| Suguihara, C | 2 |
| Gwak, M | 1 |
| Park, P | 1 |
| Kim, K | 1 |
| Lim, K | 1 |
| Jeong, S | 1 |
| Baek, C | 1 |
| Lee, J | 1 |
| Williamson, DH | 1 |
| Lopes-Vieira, O | 1 |
| Walker, B | 1 |
| Bosley, TM | 1 |
| Woodhams, PL | 1 |
| Gordon, RD | 1 |
| Balázs, R | 1 |
| Koudelová, J | 1 |
| Trojan, S | 2 |
| Fréminet, A | 1 |
| Leclerc, L | 1 |
| Poyart, C | 1 |
| Huel, C | 1 |
| Gentil, M | 1 |
| Morita, K | 2 |
| Ihnken, K | 2 |
| Buckberg, GD | 2 |
| Matheis, G | 2 |
| Sherman, MP | 2 |
| Young, HH | 2 |
| Garde, K | 1 |
| Rostrup, E | 1 |
| Toft, PB | 1 |
| Henriksen, O | 1 |
| Longuemare, MC | 1 |
| Hill, MP | 1 |
| Swanson, RA | 1 |
| Tixier, DB | 1 |
| Young, RS | 2 |
| During, MJ | 2 |
| Donnelly, DF | 1 |
| Aquila, WJ | 2 |
| Perry, VL | 1 |
| Haddad, GG | 1 |
| Nilsson, GE | 1 |
| Winberg, S | 1 |
| Castillo, J | 1 |
| Martínez, F | 1 |
| Leira, R | 1 |
| Prieto, JM | 1 |
| Lema, M | 1 |
| Noya, M | 1 |
| Díaz, L | 1 |
| Gómez, A | 1 |
| Bustos, G | 1 |
| Brooks, KJ | 1 |
| Clark, JB | 1 |
| Bates, TE | 1 |
| Payen, JF | 1 |
| LeBars, E | 1 |
| Wuyam, B | 1 |
| Tropini, B | 1 |
| Pépin, JL | 1 |
| Lévy, P | 1 |
| Décorps, M | 1 |
| Song, D | 1 |
| O'Regan, MH | 1 |
| Phillis, JW | 1 |
| Huguet, F | 1 |
| Guerraoui, A | 1 |
| Barrier, L | 1 |
| Guilloteau, D | 1 |
| Tallineau, C | 1 |
| Chalon, S | 1 |
| Navarro, H | 1 |
| Soliz, A | 1 |
| Hehre, D | 1 |
| Huang, J | 1 |
| Kugel, H | 1 |
| Heindel, W | 1 |
| Roth, B | 1 |
| Ernst, S | 1 |
| Lackner, K | 1 |
| Kivimäki, H | 1 |
| Schlenker, EH | 2 |
| Chateil, JF | 1 |
| Quesson, B | 1 |
| Brun, M | 1 |
| Thiaudière, E | 1 |
| Sarlangue, J | 1 |
| Delalande, C | 1 |
| Billeaud, C | 1 |
| Canioni, P | 1 |
| Diard, F | 1 |
| Edelstein, CL | 1 |
| Shi, Y | 1 |
| Schrier, RW | 1 |
| Weinberg, JM | 1 |
| Venkatachalam, MA | 1 |
| Roeser, NF | 1 |
| Nissim, I | 1 |
| Santini, G | 1 |
| Bruschini, C | 1 |
| Pazzagli, L | 1 |
| Pieraccini, G | 1 |
| Moneti, G | 1 |
| Chelazzi, G | 1 |
| Faulkner, A | 1 |
| Jones, CT | 1 |
| Weyne, J | 2 |
| Van Leuven, F | 2 |
| Leusen, I | 2 |
| Rau, EE | 1 |
| Shine, KI | 1 |
| Gervais, A | 1 |
| Douglas, AM | 1 |
| Amos, EC | 1 |
| Sanborn, T | 1 |
| Gavin, W | 1 |
| Berkowitz, S | 1 |
| Perille, T | 1 |
| Lesch, M | 1 |
| Zubovskaia, AM | 1 |
| Ostrovskaia, RU | 1 |
| Tsybina, NM | 1 |
| Safronova, MI | 1 |
| Chaplin, AE | 1 |
| Loxton, J | 1 |
| Tendler, D | 1 |
| Ley, E | 1 |
| Carter, AJ | 1 |
| Müller, RE | 1 |
| Rosenberg, GA | 1 |
| White, J | 1 |
| Gasparovic, C | 1 |
| Crisostomo, EA | 1 |
| Griffey, RH | 1 |
| Silverstein, FS | 1 |
| McDonald, JW | 1 |
| Bommarito, M | 1 |
| Johnston, MV | 1 |
| O'Neill, CM | 1 |
| Ball, SG | 1 |
| Vaughan, PF | 1 |
| Choi, DW | 1 |
| Nicholls, D | 1 |
| Attwell, D | 1 |
| Zeevalk, GD | 1 |
| Nicklas, WJ | 1 |
| Ransom, BR | 1 |
| Waxman, SG | 1 |
| Davis, PK | 1 |
| Van Woert, MH | 1 |
| Rosenbaum, D | 1 |
| Chung, EY | 1 |
| Meinardus-Hager, G | 1 |
| Gäde, G | 1 |
| Thurston, JH | 1 |
| Hauhart, RE | 1 |
| Krnjević, K | 1 |
| Cherubini, E | 1 |
| Ben-Ari, Y | 1 |
| Kass, IS | 1 |
| Chambers, G | 1 |
| Cottrell, JE | 1 |
| Drejer, J | 1 |
| Benveniste, H | 1 |
| Diemer, NH | 1 |
| Schousboe, A | 1 |
| Stastný, F | 1 |
| Lisý, V | 1 |
| Tomásová, H | 1 |
| Ferriero, DM | 1 |
| Arcavi, LJ | 1 |
| Sagar, SM | 1 |
| McIntosh, TK | 1 |
| Simon, RP | 1 |
| Aw, TY | 1 |
| Andersson, BS | 1 |
| Jones, DP | 1 |
| Goldman, M | 1 |
| Ballard, FJ | 1 |
| MacMillan, V | 1 |
| Nasseri, M | 1 |
| Bücherl, ES | 1 |
| Herbst, R | 1 |
| Phizackerley, PJ | 1 |
| Fixter, LM | 1 |
| Holmin, T | 1 |
| Siesjö, BK | 1 |
| Shankar, R | 1 |
| Quastel, JH | 1 |
| Hochrein, HA | 1 |
| Lossnitzer, K | 1 |
| Yoshino, Y | 2 |
| Elliott, KA | 2 |
| Bowman, RH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Lidocaine For Neuroprotection During Cardiac Surgery[NCT00938964] | 550 participants (Actual) | Interventional | 2009-07-31 | Completed | |||
| Phase III Study of Metabolic Intervention With Glutamate in Coronary Surgery II[NCT02592824] | Phase 3 | 321 participants (Actual) | Interventional | 2015-11-15 | Completed | ||
| Phase III Study of Intravenous Glutamate Infusion for Metabolic Protection of the Heart in Surgery for Unstable Coronary Artery Disease[NCT00489827] | Phase 3 | 865 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| Randomized Triple-blind Placebo Controlled Trial of Influence of Morphine or Ketamine or Saline Applied During In-hospital Cardiopulmonary Resuscitation on Early Survival and Neurological Outcome[NCT04009759] | Phase 1 | 240 participants (Anticipated) | Interventional | 2021-10-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -1.27 |
| Placebo | -0.89 |
"Center for Epidemiological Studies Depression Scale (CES-D). The CES-D is a 20-item self-report examination designed to measure symptoms of depression. Subjects rate the degree to which they have experienced a range of symptoms of depression, such as I had crying spells and I felt lonely. Scores range from 0 to 60, with higher scores indicating greater depressive symptoms. Scores greater than 16 are typically considered indicative of clinically significant depression." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.57 |
| Placebo | 0.16 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 1 year cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement (NCT00938964)
Timeframe: 1 year after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.09 |
| Placebo | 0.07 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. To quantify overall cognitive function, a baseline cognitive index was first calculated as the mean of the 5 preoperative domain scores. The cognitive index score has a mean of zero, thus any positive score is above the mean, any negative score is below the mean. A continuous change score was then calculated by subtracting the baseline from the 6-week cognitive index. The resulting outcome measure is unbounded with standard deviation of 0.35. A negative change score indicating decline and a positive score indicating improvement. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.07 |
| Placebo | 0.07 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 6.3 |
| Placebo | 6.96 |
"The DASI is a 12-item scale of functional capacity that has been found to correlate well with objective measures of maximal exercise capacity. Items reflect activities of personal care, ambulation, household tasks, sexual function, and recreational activities. Activities done with no difficulty receive scores, which are weighted and summed, for a quantitative measure of functional status. Scores range from 0 to 60; a higher-weighted score indicates better function." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -10.98 |
| Placebo | -11.67 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.05 |
| Placebo | 0.07 |
The National Institutes of Health Stroke Scale (NIHSS) is a 15-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 5 grades with 0 as normal, and there is an allowance for untestable items. The range of scores is from 0 (normal) to 42 (profound effect of stroke on patient). (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.05 |
| Placebo | 0.04 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.02 |
| Placebo | -0.02 |
The Western perioperative neurologic scale was designed to detect neurologic deficits after cardiac surgery. It includes 14 items classified into eight domains (mentation, speech, cranial nerve function, motor weakness, sensation and cerebellum, reflexes, and gait). Each item is scored from 0 (severe deficit) to3 (normal), and a maximum score of 42 indicates normal neurological function. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.04 |
| Placebo | -0.01 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.71 |
| Placebo | -1.16 |
"Perceived Social Support Scale: Twelve items indicate how strongly subjects agree that there is a special person who is around when I am in need and my family really tries to help me. Choices range from very strongly disagree to very strongly agree. Items are summed for a range of 12 to 84, with a high score meaning more social support." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 1.23 |
| Placebo | -0.49 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.20 |
| Placebo | 0.03 |
"Social Activity: This measure consisted of eight items that indicate the degree of social interaction. Sample items are How often do you talk on the telephone with friends and relatives? and How often do you attend meetings of social groups, clubs, or civic organizations? Scores range from 8 to 32. A lower score indicates more social activity." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 0.95 |
| Placebo | 1.59 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -6.70 |
| Placebo | -6.39 |
"Spielberger State Anxiety Inventory (STAI): The STAI consists of two 20-item scales that measure anxiety. Representative items include statements such as I feel nervous and I feel worried. These items are rated on a 4-point scale, based on how well they describe the patient's current or typical mood, from not at all to very much so. Scores range from 20 to 80, with higher scores indicating greater anxiety." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -7.12 |
| Placebo | -6.31 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -1.39 |
| Placebo | -1.48 |
Symptom limitations: Patients were given a list of eight symptoms and asked to rate the degree to which the symptom limited daily activities. The symptoms were angina, shortness of breath, arthritis, back trouble, leg pains, headaches, fatigue, and other. Scores range from 8 to 32, with higher scores indicating greater limitations. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.67 |
| Placebo | -0.8 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.46 |
| Placebo | -1.02 |
"Cognitive Difficulties Scale: a 39-item scale, is a self-report assessment of perceived problems in long- and short-term memory, concentration, attention, and psycho-motor coordination. Sample items are I forget errands I planned to do and I fail to recognize people I know. Scores range from 39 to 164, with higher scores indicating greater cognitive difficulty." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -3 |
| Placebo | -3.21 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | -0.15 |
| Placebo | -0.31 |
"Duke Older Americans Resources and Services Procedures- Instrumental Activities of Daily Living (OARS-IADL): This measure contains six items that assess the ability to perform important tasks for daily living (e.g., Could you prepare your own meals? Could you drive a car?). Scores range from 6 to 24. Higher scores indicate increasing difficulty in engaging in daily activities." (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Lidocaine | 2.46 |
| Placebo | 2.1 |
To characterize cognitive function over time, while minimizing potential redundancy in the cognitive measures, a factor analysis was performed on the 14 cognitive test scores from baseline. We chose a five-factor solution, which represents 5 cognitive domains: structured verbal memory, unstructured verbal memory, executive function, visual memory and attention/concentration. Each domain score is normally distributed with a mean of zero. A change score was calculated for each domain by subtracting the baseline from the 6-week score. A dichotomous outcome variable of post-operative cognitive deficit was defined as a decline of ≥1 standard deviation in 1 or more of the 5 domains. (NCT00938964)
Timeframe: Preoperative to 6 weeks after surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Lidocaine | 87 |
| Placebo | 83 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 1-year
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 1 year Change Work Activities | 1 year Change General health perception | |
| Lidocaine | -1.37 | -0.28 |
| Placebo | -1.42 | -0.43 |
The Medical Outcomes Study 36-Item Short Form Health Survey (SF-36): The SF-36 was designed to measure general health status. Two scales were used: Work Activities (four items) and General Health (one item). For the work activities scale, the reported score was the sum of four questions, each with values ranging from 1 to 4, the total score could range from 4 to 16. A higher score on Work Activities indicates more health-related problems For the general health question, the patients ranked their health from Excellent (1) to poor (5), the scale ranged from 1 to 5 with 1 being best health and 5 being worst. A high score in General Health indicates poorer health state. (NCT00938964)
Timeframe: baseline, 6-weeks
| Intervention | units on a scale (Mean) | |
|---|---|---|
| 6-Week Change Work activities | 6-Week Change General health perception | |
| Lidocaine | 2.71 | -0.004 |
| Placebo | 3 | -0.03 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -0.15 | 0.02 | -0.73 | -0.10 |
| Placebo | -0.43 | -0.73 | -0.40 | 0.19 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -4.22 | -2.46 | -0.34 | 1.21 |
| Placebo | -0.04 | 1.83 | 2.64 | 0.54 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removal and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -2.02 | 0.56 | 0.58 | 1.04 |
| Placebo | -0.08 | 0.17 | 1.19 | -0.68 |
Paired jugular venous and radial arterial blood samples were drawn at baseline, cross-clamp removal, end of cardiopulmonary bypass, and 6 hours post cross-clamp removalime points and analyzed by fluorescence-activated cell sorting to identify activated platelets. Transcerebral activation gradients were calculated by subtracting arterial values from venous values and were compared between groups (NCT00938964)
Timeframe: Baseline to 6 hours post cross-clamp removal
| Intervention | Mean linear fluorescence intensity-MLFI (Mean) | |||
|---|---|---|---|---|
| Baseline | Cross-clamp removal | End of Bypass | 6 hours post cross-clamp removal | |
| Lidocaine | -0.03 | 0.03 | 0.33 | 0.37 |
| Placebo | 0.35 | 0.43 | 0.05 | 0.27 |
Postoperative mortality was defined as mortality within 30 days of surgery. (NCT02592824)
Timeframe: up to 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 1 |
| Intravenous Saline Infusion | 6 |
suspected unexpected serious adverse reaction (NCT02592824)
Timeframe: within 24 hours from infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 0 |
"Postoperative stroke was defined as neurological or cognitive deficit with a cerebral injury verified on (Computed Tomography) CT-scan. All suspected cases of stroke underwent CT-scan.~Stroke within 24 h of surgery was defined as a stroke that occurred within 24 h of surgery or signs of a stroke, when first assessable in deeply sedated patients on a ventilator." (NCT02592824)
Timeframe: within 24 hours from surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate Infusion | 0 |
| Intravenous Saline Infusion | 4 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~In the first GLUTAMICS trial a good agreement between hemodynamic criteria for postoperative heart failure and postoperative NT-proBNP was found." (NCT02592824)
Timeframe: from the day before surgery to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 5390 |
| Intravenous Saline Infusion | 6452 |
"Postoperative increase of NT-proBNP reflects postoperative myocardial dysfunction sustained in association with surgery. NT-proBNP usually peaks on the third to fourth postoperative day after coronary artery bypass surgery.~Previous observations suggest a blunted effect of glutamate in diabetic hearts." (NCT02592824)
Timeframe: from preoperative level to the third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4503 |
| Intravenous Saline Infusion | 6825 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: first postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 4438 |
| Intravenous Saline Infusion | 4420 |
Postoperative NT-proBNP reflects postoperative myocardial dysfunction. (NCT02592824)
Timeframe: third postoperative day
| Intervention | ng/L (Mean) |
|---|---|
| Intravenous Glutamate Infusion | 8055 |
| Intravenous Saline Infusion | 8804 |
Number of patients with atrial fibrillation recorded postoperatively (NCT00489827)
Timeframe: Hospital stay
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 147 |
| Saline Infusion | 152 |
ICU duration of stay (hours) (NCT00489827)
Timeframe: ICU stay
| Intervention | hours (Median) |
|---|---|
| Intravenous Glutamate | 21 |
| Saline Infusion | 21 |
(NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 31 |
| Saline Infusion | 25 |
Incidence of Postoperative stroke < 24 hours of surgery verifed by CT-scan (NCT00489827)
Timeframe: 24 hours
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 4 |
| Saline Infusion | 6 |
Hemodynamic instability despite inotropes or need for IABP at the end of surgery in patients with severely reduced left ventricular ejection fraction (LVEF<0.40) (NCT00489827)
Timeframe: End of surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 1 |
| Saline Infusion | 5 |
maximum p-creatinine value recorded postoperatively < 30 days (NCT00489827)
Timeframe: 30 days
| Intervention | µmol/L (Mean) |
|---|---|
| Intravenous Glutamate | 106 |
| Saline Infusion | 106 |
Severe circulatory failure according to prespecified criteria as judged by a blinded endpoints committee in CCS class IV patients (NCT00489827)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Intravenous Glutamate | 3 |
| Saline Infusion | 16 |
p-CK-MB postoperative day 1, p-troponin-T postoperative day 3 (NCT00489827)
Timeframe: perioperative
| Intervention | µg/L (Median) | |
|---|---|---|
| CK-MB day 1 | Troponin-T day 3 | |
| Intravenous Glutamate | 14 | 0.27 |
| Saline Infusion | 14 | 0.24 |
Mixed venous oxygen saturation (SvO2) measured at weaning from cardiopulmonary bypass and on arrival to ICU (NCT00489827)
Timeframe: Until arrival to ICU
| Intervention | percentage of saturated hemoglobin (Mean) | |
|---|---|---|
| SvO2 at weaning from CPB | SvO2 on arrival to ICU | |
| Intravenous Glutamate | 72.0 | 65.0 |
| Saline Infusion | 72.2 | 64.9 |
2 reviews available for aspartic acid and Hypoxia
| Article | Year |
|---|---|
Cerebral hypoxia: some new approaches and unanswered questions.
Topics: Animals; Aspartic Acid; Brain Diseases; Cell Survival; Cerebrovascular Circulation; Excitatory Amino | 1990 |
The release and uptake of excitatory amino acids.
Topics: Animals; Aspartic Acid; Biological Transport; Calcium; Exocytosis; Glutamates; Glutamic Acid; Humans | 1990 |
1 trial available for aspartic acid and Hypoxia
| Article | Year |
|---|---|
Creatine supplementation enhances corticomotor excitability and cognitive performance during oxygen deprivation.
Topics: Adult; Aspartic Acid; Blood Pressure; Cognition Disorders; Creatine; Dietary Supplements; Evoked Pot | 2015 |
85 other studies available for aspartic acid and Hypoxia
| Article | Year |
|---|---|
Adaptive stimulation of macropinocytosis overcomes aspartate limitation in cancer cells under hypoxia.
Topics: Aspartic Acid; Cell Line, Tumor; Humans; Hypoxia; Pancreatic Neoplasms; Proto-Oncogene Proteins p21( | 2022 |
Glutamine Is Required for M1-like Polarization of Macrophages in Response to Mycobacterium tuberculosis Infection.
Topics: Aspartic Acid; Carbon; Glucose; Glutamine; Glycolysis; Humans; Hypoxia; Macrophages; Mycobacterium t | 2022 |
Hypoxia-responsive nanocarriers for chemotherapy sensitization via dual-mode inhibition of hypoxia-inducible factor-1 alpha.
Topics: Antineoplastic Agents; Aspartic Acid; Caspase 3; Cell Hypoxia; Cell Line, Tumor; Cytochromes c; Dicu | 2022 |
Modulation of muscarinic receptors by anisodine hydrobromide in cerebral ischemia.
Topics: Animals; Aspartic Acid; Calcium; Cerebral Infarction; Hypoxia; Rats; Reactive Oxygen Species; Recept | 2023 |
The mitochondrial NADH shuttle system is a targetable vulnerability for Group 3 medulloblastoma in a hypoxic microenvironment.
Topics: Aspartic Acid; Cerebellar Neoplasms; Child; Humans; Hypoxia; Malates; Medulloblastoma; NAD; Oxygen; | 2023 |
Neuroprotection Promoted by Guanosine Depends on Glutamine Synthetase and Glutamate Transporters Activity in Hippocampal Slices Subjected to Oxygen/Glucose Deprivation.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Aspartic Acid; Dose-Response Relati | 2016 |
Precursors and inhibitors of hydrogen sulfide synthesis affect acute hypoxic pulmonary vasoconstriction in the intact lung.
Topics: Alkynes; Animals; Aspartic Acid; Blood Pressure; Cystathionine beta-Synthase; Cystathionine gamma-Ly | 2012 |
Chronic perinatal hypoxia reduces glutamate-aspartate transporter function in astrocytes through the Janus kinase/signal transducer and activator of transcription pathway.
Topics: Age Factors; Amino Acid Transport System X-AG; Animals; Animals, Newborn; Aspartic Acid; Astrocytes; | 2011 |
Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis.
Topics: Aspartic Acid; Bacterial Proteins; Gene Expression Regulation, Bacterial; Gene Targeting; Genes, Rep | 2003 |
[Comparison of the activities of diethylaminoethyl aspartate and diethylaminoethyl nicotinate with respect to the cardiac manifestations of acute hypoxia].
Topics: Aspartic Acid; Heart; Hypoxia; Niacin; Nicotinic Acids | 1962 |
[Effect of potassium and magnesium salts of 1-aspartic acid on blood ammonia levels, oxygen consumption and tolerance time in hypoxia].
Topics: Ammonia; Aspartic Acid; Energy Metabolism; Humans; Hypoxia; Liver Function Tests; Magnesium; Oxygen | 1963 |
[EFFECT OF LOWERED BAROMETRIC PRESSURE ON SOME ASPECTS OF THE CEREBRAL NITROGEN METABOLISM].
Topics: Altitude; Amino Acids; Aminobutyrates; Aspartic Acid; Atmospheric Pressure; Brain; Glutamates; Hypox | 1963 |
Effects of acute hypoxic conditions on extracellular excitatory amino acids and dopamine in the striatum of freely-moving rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Acute Disease; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Ex | 2003 |
Localization and function of the brain excitatory amino acid transporter type 1 in cardiac mitochondria.
Topics: Adenoviridae; Animals; Aspartic Acid; Blotting, Northern; Brain; Cells, Cultured; Coloring Agents; C | 2004 |
Ischemia and reoxygenation induced amino acid release release and tissue damage in the slices of rat corpus striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Brain; Calcium; Citrulline; Corpus Striatum; Female; gamma-Amin | 2004 |
TREATMENT OF FATIGUE IN GENERAL PRACTICE: A DOUBLE BLIND STUDY.
Topics: Aspartic Acid; Double-Blind Method; Family Practice; Fatigue; Hypoxia; Magnesium; Mice; Pharmacology | 1964 |
Cerebral oxidative stress and depression of energy metabolism correlate with severity of diffuse brain injury in rats.
Topics: Animals; Ascorbic Acid; Aspartic Acid; Biomarkers; Brain; Brain Chemistry; Brain Injuries; Chromatog | 2005 |
In vivo effect of chronic hypoxia on the neurochemical profile of the developing rat hippocampus.
Topics: Age Factors; Analysis of Variance; Animals; Animals, Newborn; Aspartic Acid; Body Weight; Brain Chem | 2005 |
Growth restriction and the cerebral metabolic response to acute hypoxia of chick embryos in-ovo: a proton magnetic resonance spectroscopy study.
Topics: 3-Hydroxybutyric Acid; Alanine; Animals; Aspartic Acid; Cerebellum; Chick Embryo; Fetal Hypoxia; Hyp | 2005 |
Chaperonin GroEL and its mutant D87K protect from ischemia in vivo and in vitro.
Topics: Analysis of Variance; Animals; Animals, Newborn; Aspartic Acid; Astrocytes; Blotting, Western; Brain | 2006 |
Ionotropic glutamate receptors and glutamate transporters are involved in necrotic neuronal cell death induced by oxygen-glucose deprivation of hippocampal slice cultures.
Topics: Amino Acid Transport System X-AG; Analysis of Variance; Animals; Animals, Newborn; Aspartic Acid; Ce | 2005 |
Excitatory amino acid release and electrocortical brain activity after hypoxemia in near-term lambs.
Topics: Animals; Animals, Newborn; Aspartic Acid; Blood Glucose; Brain; Electroencephalography; Female; Gest | 2006 |
Taurine attenuates D-[3H]aspartate release evoked by depolarization in ischemic corticostriatal slices.
Topics: Animals; Aspartic Acid; Brain Ischemia; Cerebral Cortex; Corpus Striatum; Dose-Response Relationship | 2006 |
Neuroprotective potential of ceftriaxone in in vitro models of stroke.
Topics: Analysis of Variance; Animals; Animals, Newborn; Anti-Bacterial Agents; Aspartic Acid; Ceftriaxone; | 2007 |
Brainstem amino acid neurotransmitters and ventilatory response to hypoxia in piglets.
Topics: Acid-Base Equilibrium; Amino Acids; Animals; Animals, Newborn; Aspartic Acid; Blood Pressure; Carbon | 2008 |
The effects of dantrolene on hypoxic-ischemic injury in the neonatal rat brain.
Topics: Animals; Animals, Newborn; Apoptosis; Aspartic Acid; Brain; Carotid Artery, Common; Creatine; Dantro | 2008 |
Concentrations of free glucogenic amino acids in livers of rats subjected to various metabolic stresses.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Diabetes Mellitus, Experimental; Gluconeogenesis; Glut | 1967 |
Effects of anoxia on the stimulated release of amino acid neurotransmitters in the cerebellum in vitro.
Topics: Amino Acids; Animals; Aspartic Acid; Brain Ischemia; Cerebellum; Female; gamma-Aminobutyric Acid; Gl | 1983 |
Effect of single and repeated aerogenic hypoxia on the content of amino acids in the rat brain.
Topics: Age Factors; Amino Acids; Animals; Aspartic Acid; Atmospheric Pressure; Brain; Female; gamma-Aminobu | 1980 |
Alanine and succinate accumulation in the perfused rat heart during hypoxia.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Alanine; Animals; Aspartic Acid; Citrates; Fumarates; | 1980 |
Studies of hypoxemic/reoxygenation injury: without aortic clamping. VIII. Counteraction of oxidant damage by exogenous glutamate and aspartate.
Topics: Alkadienes; Animals; Aspartic Acid; Cardiopulmonary Bypass; Glutamic Acid; Hemodynamics; Hypoxia; Li | 1995 |
Cerebral energy metabolism during hypoxaemia. A 31P and 1H magnetic resonance study.
Topics: Adult; Aspartic Acid; Brain; Choline; Creatine; Energy Metabolism; Hemodynamics; Humans; Hydrogen-Io | 1995 |
Glycolysis can prevent non-synaptic excitatory amino acid release during hypoxia.
Topics: Adenosine Triphosphate; Animals; Aspartic Acid; Astrocytes; Azides; Cells, Cultured; Energy Metaboli | 1994 |
Cardiopulmonary dysfunction produced by reoxygenation of immature hypoxemic animals supported by cardiopulmonary bypass. Prevention by intravenous metabolic pretreatment.
Topics: Animals; Aspartic Acid; Cardiopulmonary Bypass; Catalase; Drug Combinations; Glucose; Glutamates; Gl | 1993 |
Effect of anoxia on excitatory amino acids in brain slices of rats and turtles: in vitro microdialysis.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Brain; Brain Stem; Dialysis; Glutamates; Glutamic Acid | 1993 |
Changes in the brain levels of GABA and related amino acids in anoxic shore crab (Carcinus maenas).
Topics: Alanine; Amino Acids, Branched-Chain; Animals; Aspartic Acid; Brachyura; Brain Chemistry; gamma-Amin | 1993 |
[Changes in neuroexcitatory amino acids during and between migraine attacks].
Topics: Adult; Amino Acids; Aspartic Acid; Brain; Glutamates; Humans; Hypoxia; Middle Aged; Migraine Disorde | 1994 |
Lidocaine reduces the hypoxia-induced release of an excitatory amino acid analog from rat striatal slices in superfusion.
Topics: Animals; Aspartic Acid; Corpus Striatum; Hypoxia; Lidocaine; Male; Neurotoxins; Rats; Rats, Sprague- | 1995 |
Assessment of energy metabolism in the developing brain following aglycemic hypoxia by 1H and 31P NMR.
Topics: Alanine; Animals; Aspartic Acid; Calcium; Calcium Channel Blockers; Cerebral Cortex; Energy Metaboli | 1996 |
Lactate accumulation during moderate hypoxic hypoxia in neocortical rat brain.
Topics: Animals; Aspartic Acid; Brain; Energy Metabolism; Female; Hypoxia; Lactic Acid; Rats; Rats, Sprague- | 1996 |
Release of the excitotoxic amino acids, glutamate and aspartate, from the isolated ischemic/anoxic rat heart.
Topics: Animals; Aspartic Acid; Brain; Excitatory Amino Acids; Glutamic Acid; Hypoglycemia; Hypoxia; Male; M | 1996 |
Changes in excitatory amino acid levels and tissue energy metabolites of neonate rat brain after hypoxia and hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Aspartic Acid; Brain; Brain Ischemia; Energy Metabolism; Excitatory Amino | 1998 |
Release of endogenous glutamate, aspartate, GABA, and taurine from hippocampal slices from adult and developing mice under cell-damaging conditions.
Topics: Aging; Animals; Aspartic Acid; Brain Ischemia; Female; gamma-Aminobutyric Acid; Glutamic Acid; Hippo | 1998 |
Effect of L-aspartate on the ventilatory response to hypoxia in sedated newborn piglets.
Topics: Anesthesia; Animals; Animals, Newborn; Aspartic Acid; Hypoxia; Injections, Intravenous; Pulmonary Ve | 1998 |
Proton MR spectroscopy in infants with cerebral energy deficiency due to hypoxia and metabolic disorders.
Topics: Aspartic Acid; Basal Ganglia; Brain; Brain Diseases, Metabolic; Child, Preschool; Follow-Up Studies; | 1998 |
D-aspartate uptake in nervous tissue is inhibited in hypoxic conditions.
Topics: Animals; Aspartic Acid; Biomarkers; Brain; Cell Hypoxia; Female; Hypoxia; In Vitro Techniques; Male; | 1998 |
Aspartic acid in the arcuate nucleus attenuates the depressive effects of naloxone on ventilation.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Aspartic Acid; Hypercapnia; Hypoxia; Injections, Subcutane | 1998 |
Localised proton magnetic resonance spectroscopy of the brain after perinatal hypoxia: a preliminary report.
Topics: Aspartic Acid; Asphyxia; Brain; Choline; Creatine; Follow-Up Studies; Humans; Hypoxia; Infant, Newbo | 1999 |
Role of caspases in hypoxia-induced necrosis of rat renal proximal tubules.
Topics: Animals; Aspartic Acid; Calpain; Caspase 1; Caspase Inhibitors; Caspases; Coumarins; Cysteine Protei | 1999 |
Mitochondrial dysfunction during hypoxia/reoxygenation and its correction by anaerobic metabolism of citric acid cycle intermediates.
Topics: Adenosine Triphosphate; Animals; Aspartic Acid; Benzimidazoles; Carbocyanines; Citric Acid Cycle; Fl | 2000 |
Metabolic responses of the limpet Patella caerulea (L.) to anoxia and dehydration.
Topics: Acetates; Adaptation, Physiological; Alanine; Animals; Aspartic Acid; Dehydration; Hypoxia; Mollusca | 2001 |
Some effects of glucose concentration and anoxia on glycolysis and metabolite concentrations in the perfused liver of fetal guinea pig.
Topics: Adenine Nucleotides; Animals; Aspartic Acid; Citric Acid Cycle; Female; Fructosediphosphates; Gestat | 1978 |
Organic acids in the brain in hypoxemia.
Topics: Ammonia; Animals; Aspartic Acid; Brain; gamma-Aminobutyric Acid; Glutamates; Glutamine; Hypoxia; Ket | 1976 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Enhanced mechanical recovery of anoxic and ischemic myocardium by amino acid perfusion.
Topics: Amino Acids; Animals; Arginine; Aspartic Acid; Coronary Disease; Creatine; Glutamates; Hypoxia; Male | 1979 |
Augmented conversion of aspartate and glutamate to succinate during anoxia in rabbit heart.
Topics: Animals; Aspartic Acid; Carbon Dioxide; Fumarates; Glutamates; Hypoxia; Kinetics; Myocardium; Rabbit | 1979 |
Brain amino acids in conscious rats in chronic normocapnic and hypocapnic hypoxemia.
Topics: Amino Acids; Ammonia; Animals; Aspartic Acid; Brain Chemistry; Carbon Dioxide; gamma-Aminobutyric Ac | 1977 |
[Effect of succinic semialdehyde on nitrogen metabolism of animal brain tissue during hypoxia].
Topics: Alanine; Amino Acids; Ammonia; Animals; Aspartic Acid; Brain; gamma-Aminobutyric Acid; Glutamates; G | 1976 |
Tissue differences in the response of the mussel Mytilus edulis to experimentally induced anaerobiosis.
Topics: Aerobiosis; Alanine; Anaerobiosis; Animals; Aspartic Acid; Bivalvia; Gills; Glutamates; Hypoxia; Liv | 1976 |
Hypoxia increases extracellular concentrations of excitatory and inhibitory neurotransmitters in subsequently induced seizure: in vivo microdialysis study in the rabbit.
Topics: Animals; Aspartic Acid; Bicuculline; Brain; Dialysis; Electroencephalography; gamma-Aminobutyric Aci | 1992 |
Activation of excitatory amino acid receptors cannot alone account for anoxia-induced impairment of protein synthesis in rat hippocampal slices.
Topics: Animals; Aspartic Acid; Carbon Radioisotopes; Dizocilpine Maleate; Glutamates; Glutamic Acid; Hippoc | 1991 |
Effect of hypoxia on cerebral metabolites measured by proton nuclear magnetic resonance spectroscopy in rats.
Topics: Animals; Aspartic Acid; Brain; Hyperglycemia; Hypoglycemia; Hypoxia; Lactates; Lactic Acid; Magnetic | 1991 |
Effects of hypoxia-ischemia and MK-801 treatment on the binding of a phencyclidine analogue in the developing rat brain.
Topics: Animals; Animals, Newborn; Aspartic Acid; Autoradiography; Binding Sites; Brain; Brain Ischemia; Dib | 1990 |
Effects of ischaemic conditions on the uptake of catecholamine and amino acid neurotransmitters.
Topics: Aspartic Acid; Humans; Hypoxia; Ischemia; Neurons; Neurotransmitter Agents; Norepinephrine; Tumor Ce | 1990 |
Chemically induced hypoglycemia and anoxia: relationship to glutamate receptor-mediated toxicity in retina.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Aspartic Acid; Chick Embryo; Electron Transport; Glyco | 1990 |
Anoxic injury of CNS white matter: protective effect of ketamine.
Topics: Action Potentials; Animals; Aspartic Acid; Central Nervous System Diseases; Glutamates; Hypoxia; Ket | 1990 |
Biochemistry and therapeutics of posthypoxic myoclonus.
Topics: 5-Hydroxytryptophan; Adrenocorticotropic Hormone; Aspartic Acid; Benzodiazepines; Carbidopa; Electro | 1986 |
The pyruvate branchpoint in the anaerobic energy metabolism of the jumping cockle Cardium tuberculatum L.: D-lactate formation during environmental anaerobiosis versus octopine formation during exercise.
Topics: Alanine; Anaerobiosis; Animals; Arginine; Aspartic Acid; Energy Metabolism; Fatty Acids, Volatile; G | 1986 |
Valproate doubles the anoxic survival time of normal developing mice: possible relevance to valproate-induced decreases in cerebral levels of glutamate and aspartate, and increases in taurine.
Topics: Animals; Animals, Suckling; Aspartic Acid; Body Weight; Brain; Glucose; Glutamates; Hypoxia; Mice; T | 1989 |
Anoxia on slow inward currents of immature hippocampal neurons.
Topics: Aging; Animals; Animals, Newborn; Aspartic Acid; Calcium Channels; Electric Conductivity; Hippocampu | 1989 |
The N-methyl-D-aspartate antagonists aminophosphonovaleric acid and MK-801 reduce anoxic damage to dentate granule and CA1 pyramidal cells in the rat hippocampal slice.
Topics: 2-Amino-5-phosphonovalerate; Adenosine Triphosphate; Animals; Anticonvulsants; Aspartic Acid; Dibenz | 1989 |
Cellular origin of ischemia-induced glutamate release from brain tissue in vivo and in vitro.
Topics: Animals; Aspartic Acid; Astrocytes; Brain; Calcium; Cells, Cultured; Cerebellum; Dialysis; Glutamate | 1985 |
Effects of short-term and prolonged aerogenic hypoxia on gamma-glutamyl transpeptidase activity in the brain, liver, and biological fluids of young rats.
Topics: Altitude; Animals; Aspartic Acid; Body Fluids; Brain; Female; gamma-Glutamyltransferase; Glutamates; | 1985 |
Selective sparing of NADPH-diaphorase neurons in neonatal hypoxia-ischemia.
Topics: Animals; Animals, Newborn; Aspartic Acid; Brain Ischemia; Cerebral Cortex; Corpus Striatum; Hypoxia; | 1988 |
Mitochondrial transmembrane ion distribution during anoxia.
Topics: Adenine Nucleotides; Animals; Aspartic Acid; Citrates; Cytosol; Glutamates; Hydrogen-Ion Concentrati | 1987 |
Aspartic acid administered neonatally affects ventilation of male and female rats differently.
Topics: Animals; Animals, Newborn; Aspartic Acid; Female; Hypercapnia; Hypoxia; Male; Pulmonary Ventilation; | 1986 |
Regulation of gluconeogenesis during exposure of young rats to hypoxic conditions.
Topics: Acetoacetates; Adenine Nucleotides; Adenosine Triphosphate; Animals; Aspartic Acid; Gluconeogenesis; | 1971 |
The effect of combined hypocapnia and hypoxemia upon the energy metabolism of the brain.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Animals; Aspartic Acid; Body | 1974 |
[Practical experiences using procaine magnesium aspartate in open heart surgery].
Topics: Adolescent; Adult; Aspartic Acid; Biopsy; Child; Coronary Disease; Electrocardiography; Extracorpore | 1973 |
Effects of anoxia in vitro on cellular respiration of brain cortex.
Topics: Age Factors; Amino Acids; Anaerobiosis; Animals; Aspartic Acid; Cerebral Cortex; Chromatography, Gel | 1973 |
Influence of hypoxia on cerebral energy state in rats with porta-caval anastomosis.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adenosine Triphosphate; Ammonia; Animals; Aspartic A | 1974 |
Effects of tetrodotoxin and anaesthetics on brain metabolism and transport during anoxia.
Topics: Action Potentials; Amobarbital; Anesthetics; Anesthetics, Local; Animals; Aspartic Acid; Calcium; Ca | 1972 |
The interrelation between myocardial metabolism and heart failure.
Topics: Animals; Aspartic Acid; Calcium; Digitalis Glycosides; Edema; Glucose; Glycolysis; Guinea Pigs; Hear | 1969 |
Effects of various conditions on the movement of carbon atoms derived from glucose into and out of protein in rat brain.
Topics: Alanine; Amino Acids; Animals; Aspartic Acid; Autoanalysis; Brain; Carbon Isotopes; Cerebral Cortex; | 1970 |
Incorporation of carbon atoms from glucose into free amino acids in brain under normal and altered conditions.
Topics: Alanine; Amino Acids; Aminobutyrates; Animals; Aspartic Acid; Autoanalysis; Brain; Carbon Isotopes; | 1970 |
Effects of diabetes, fatty acids, and ketone bodies on tricarboxylic acid cycle metabolism in the perfused rat heart.
Topics: Animals; Aspartic Acid; Carbon Dioxide; Citrates; Citric Acid Cycle; Coenzyme A; Diabetes Mellitus, | 1966 |